GlaxoSmithKline has agreed to buy US cancer specialist Tesaro for $5.1 billion, marking a major biotech investment by Chief Executive Emma Walmsley as she seeks to rebuild the group’s pharmaceuticals business.
GSK has lagged rivals in recent years in producing multibillion-dollar blockbusters and it largely sat out a spate of deal-making by rival drugmakers under previous CEO Andrew Witty. That is a situation Walmsley now wants to change. Britain’s biggest drugmaker is paying $75 a share for the business, an 110 per cent premium to the 30-day average price. It is also taking on Tesaro’s debt.
Boston-based Tesaro has long been seen as a potential takeover target, with other suggested acquirers in the past including Switzerland’s Roche.
The definitive agreement to acquire Tesaro comes on the same day as GSK sold its India-focussed Horlicks nutrition business to Unilever, freeing up cash for pharmaceuticals investment.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.